Delivery to
Hello, User
Account & Orders
Shop By Category
Call for Order
Shop By Category
ফার্মেসীর জন্য পাইকারি দামে ঔষধ কিনতে রেজিস্টেশন করুন
0 People recently viewed this

Out of Stock
Currently unavailable, please request or choose another variant.
Select Quantity
Sefety Advices
Caution is advised when consuming alcohol with Relyto 100 IV. Please consult your doctor.
Relyto 100 IV may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Relyto 100 IV is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
It is not known whether Relyto 100 IV alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Relyto 100 IV is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Relyto 100 IV may not be needed in these patients. Please consult your doctor.
There is limited information available on the use of Relyto 100 IV in patients with liver disease. Please consult your doctor. Use of Relyto 100 IV is not recommended in patients with the active liver disease or those who had viral hepatitis as it can reactivate the infection.
Medical Overview
Relyto 100 IV is used in the treatment of non-Hodgkin lymphoma (NHL), rheumatoid arthritis, blood cancer (chronic lymphocytic leukemia), granulomatosis with polyangiitis and microscopic polyangiitis. Relyto 100 IV is given as an injection under the supervision of doctor. You must take it in a dose as advised by the doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. The most common side effects of this medicine include headache, weakness, edema, infection, and hair loss. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with hepatitis B. Before taking it, tell your doctor if you have heart disease, liver, or planning surgery or vaccination or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
Uses of Relyto 100 IV
  • Non-Hodgkin lymphoma (NHL)
  • Rheumatoid arthritis
  • Blood cancer (Chronic lymphocytic leukemia)
  • Granulomatosis with polyangiitis
  • Microscopic polyangiitis
Side effects of Relyto 100 IV
  • Headache
  • Weakness
  • Edema (swelling)
  • Infection
  • Hair loss
  • Itching
  • Chills
  • Febrile neutropenia
  • Decreased white blood cell count (neutrophils)
  • Infusion reaction
  • Increased risk of infection
  • Decreased blood cells (red cells, white cells, and platelets)
How to use Relyto 100 IV
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Relyto 100 IV works
Relyto 100 IV is a monoclonal antibody. It works by targeting the unwanted activity of immune cells (B cells) in rheumatoid arthritis and certain types of cancers.
What if you forget to take Relyto 100 IV?
If you miss a dose of Relyto 100 IV, please consult your doctor.
Quick Tips
  • It is given as a drip (intravenous infusion) by your doctor or nurse.
  • You may be given some painkillers, antihistamine and possibly steroids before the drip to help prevent infusion reaction.
  • Your doctor may get blood tests done to check for hepatitis B before treatment and to monitor your blood cells during treatment with this medicine.
  • Inform your doctor immediately if you notice any signs of infection such as fever, sore throat or rash.
  • Inform your doctor if you are pregnant, planning to conceive or breastfeeding.
  • Inform your doctor if you have any heart rhythm problems, if you are having surgery or if you plan to get any vaccinations.
Brief Description
Non-Hodgkin's lymphoma; follicular lymphoma
Reconstitution: Dilute the appropriate dose w/ sodium chloride 0.9% or glucose 5% to a final concentration of between 1 and 4 mg/mL. IV Administration Consider premedication (ie, paracetamol and diphenhydramine, or glucocorticoids for RA) before each infusion Administer by slow IV infusion only; do not administer as an IV First IV infusion rate: Start 50 mg/hr; increase by 50 mg/hr q30min, not to exceed 400 mg/hr Subsequent IV infusions (90 minutes) Standard IV infusions: Start 100 mg/hr, increase by 100 mg/hr q30min, not to exceed 400 mg/hr; institutional protocols may allow faster increments
Adult Dose
Intravenous Non-Hodgkin Lymphoma Recommended dose for NHL 375 mg/m² IV infusion according to the following schedules Relapsed or refractory low-grade or follicular, CD20-positive, B-cell NHL: Once weekly x4-8 doses Retreatment for relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL: Once weekly x4 doses Previously untreated, follicular, CD20-positive, B-cell NHL: Administer on Day 1 of each chemotherapy cycle for up to 8 doses; with complete or partial response, initiate maintenance 8 weeks following completion of combination chemotherapy as a single-agent q8weeks for 12 doses Nonprogressing, low-grade, CD20-positive, B-cell NHL, after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy, administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses Diffuse large B-cell NHL: Administer on Day 1 of each cycle of chemotherapy for up to 8 infusions Chronic Lymphocytic Leukemia Indicated for untreated and previously treated CD20-positive CLL; combined therapy with fludarabine and cyclophosphamide (FC) 375 mg/m² IV infusion on day 1 of 1st cycle (for 1st cycle, administer 1 day before chemotherapy with FC), THEN 500 mg/m² IV on day 1 of subsequent cycles (administer on same day as chemotherapy with FC) Repeat q28 days x6 cycles Fludarabine & cyclophosphamide dosage Fludarabine: 25 mg/m² IV qDay x 3 days Cyclophosphamide: 250 mg/m² IV qDay x3 days Repeat q28 days x 6 cycles Rheumatoid Arthritis 1000 mg IV infusion, repeat after 2 week (2 infusions separated by 2 week is 1 course) Repeat course q24weeks or based on clinical evaluation (but no sooner than 16 weeks) Used in combo with methotrexate Premedicate with glucocorticoids 30 minutes before infusion to reduce infusion rxn Not to exceed 1000 mg/dose
Child Dose
Safety and efficacy not established
Lactation. Type I hypersensitivity or anaphylactic reactions to murine proteins or component of the formulation.
Mode of Action
Rituximab is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation. It binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.
Extensive tumor burden, pulmonary tumor infiltration or pulmonary insufficiency; history of cardiac disease; effective contraception during and up to 12 mth after treatment; pregnancy. Monitor CBC and platelet counts regularly. Premedication with analgesics, antihistamines and corticosteroids may be recommended. Monitor for signs of active infection or hepatitis in hepatitis B carriers. Discontinue treatment if viral hepatitis develops. Lactation: not known if excreted in breast milk, do not nurse
Side Effect
>10% NHL Angioedema (11%), hypotension (10%), Asthenia (26%), chills (33%), dizziness (10%), fever (53%), headache (19%) Pruritus (14%), rash (15%), Abdominal pain (14%), diarrhea (10%), nausea (23%), vomiting (10%) Leukopenia (14%), lymphopenia (48%), neutropenia (14%), thrombocytopenia (12%), Back pain (10%), myalgia (10%) Cough (13%), rhinitis (12%), Infection (31%), night sweats (15%) 1-10% NHL Edema,Flushing,Hypertension,Anxiety,Anemia,Elevated LDH,Hyperglycemia,Bronchospasm, dyspnea, sinusitis, throat irritation, urticaria,RA (Rituximab+Methotrexate vs Methotrexate Alone) Hypertension,Anxiety, asthenia, chills, migraine, paresthesia, pyrexia,Pruritus, urticaria,Dyspepsia, nausea, upper abd pain,Hypercholesterolemia,Arthralgia,Rhinitis, throat irritation, URI Frequency Not Defined Tumor lysis syndrome,Lymphoid malignancies,Hypogammaglobulinemia Potentially Fatal: Pulmonary or cardiac toxicity during infusion; severe mucocutaneous reactions; severe cytokine release syndrome associated with tumor lysis syndrome. Toxic epidermal necrolysis.
Increased risk of renal toxicity w/ cisplatin. Potentially Fatal: May decrease the efficacy of vaccines and increase the risk of infections in patients immunised w/ live vaccines.
ফার্মেসীর জন্য পাইকারি দামে ঔষধ কিনতে রেজিস্টেশন করুন
0 People recently viewed this

Out of Stock
Currently unavailable, please request or choose another variant.
Select Quantity
Additional Offers
For purchasing above ৳5000+
For purchasing above ৳4000+
For purchasing above ৳3000+
For purchasing above ৳2000+
For purchasing above ৳1000+
Similar Products
see all
More from Incepta Pharmaceuticals Ltd.
see all
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.